Daclizumab is a humanized monoclonal antibody that binds to the alpha chain (CD25) of the interleukin-2 (IL-2) receptor on activated T cells, which are white blood cells that play a role in immune-mediated processes in the body.

We believe this antibody mechanism has potential in a wide range of inflammatory diseases, including multiple sclerosis, and that it may also be effective as a maintenance therapy in patients who have undergone an organ transplant. We have created a new high-yield manufacturing process and a higher concentration formulation required to move daclizumab into a broader area of immunological disease.

Currently, we have a worldwide strategic development collaboration for daclizumab with Biogen Idec in multiple sclerosis and other immunologic disease areas in which we are sharing development costs and commercial rights.  Outside of the Biogen Idec collaboration, Facet Biotech wholly owns the rights for daclizumab in respiratory (asthma) and transplant maintenance indications.  

Daclizumab is currently in Phase 2 development for multiple sclerosis and under consideration for further development in transplant maintenance.

CHOICE Presentation